Ozempic (Semaglutide) Insurance Denial Appeal Guide

Ozempic Coverage Landscape

Ozempic has two common denial scenarios:

1. On-label (type 2 diabetes): Usually covered but may require step therapy (try metformin first)
2. Off-label (weight loss): Frequently denied — Wegovy is the FDA-approved weight loss version

Common Denial Reasons

• Prior authorization not obtained
• Step therapy: metformin → sulfonylurea → then GLP-1
• Formulary tier: may be on a high-cost specialty tier
• Off-label use: not FDA-approved for weight loss
• Quantity limits exceeded

Appeal Strategy for Diabetes Patients

1. Document HbA1c levels and response to prior medications
2. Show failure or intolerance of first-line agents
3. Provide endocrinologist letter supporting GLP-1 therapy
4. Cite ADA Standards of Medical Care in Diabetes
5. Reference cardiovascular benefits (SUSTAIN-6 trial: 26% MACE reduction)

Appeal Strategy for Weight Management

• Request Wegovy instead (same drug, FDA-approved for weight loss)
• If Wegovy is also denied, appeal on medical basis for both
• Document obesity-related comorbidities
• Cite physician's clinical judgment on drug selection